Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) was upgraded by stock analysts at Leerink Partnrs to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks.com reports.
A number of other equities research analysts have also issued reports on ORKA. Leerink Partners began coverage on Oruka Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $44.00 target price on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price objective on the stock. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday. They issued an “outperform” rating and a $41.00 target price for the company. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.25.
Read Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Trading Down 4.1 %
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More
- Five stocks we like better than Oruka Therapeutics
- How to Find Undervalued Stocks
- How Much Can You Make in Stocks in One Month?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- This Is the Top Large-Cap Stock Insiders Are Buying
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.